Orthobiologics Market Report 2026

The orthobiologics market size has grown strongly in recent years. It will grow from $7.48 billion in 2025 to $7.94 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to limited availability of effective regenerative therapies, increasing prevalence of musculoskeletal disorders, growing adoption of surgical interventions like spinal fusion, rising awareness of orthobiologics among orthopedic surgeons, early use of autografts and allografts in clinical practice.

The orthobiologics market size is expected to see strong growth in the next few years. It will grow to $9.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to expanding pipeline of cellular and exosome-based orthobiologic products, increasing investment in tissue engineering and regenerative medicine, rising adoption of minimally invasive and outpatient orthopedic procedures, growing demand for personalized and targeted orthobiologic treatments, expansion of orthobiologics use in dental and maxillofacial applications. Major trends in the forecast period include rising adoption of platelet-rich plasma (prp) and bone morphogenetic proteins (bmps), increasing use of synthetic bone substitutes for fracture repair and spinal fusion, growing preference for cellular allografts and stem cell-based therapies, rising focus on minimally invasive orthopedic procedures, increasing emphasis on accelerated recovery and improved clinical outcomes.

The rising number of sports injuries and road accidents is expected to drive growth in the orthobiologics market in the coming years. These incidents, which often affect the musculoskeletal system, are fueled by factors such as distracted driving, speeding, poor road conditions, overuse, improper sports equipment, and lack of proper training. Orthobiologics aid in the treatment of these injuries by promoting faster and more effective healing of musculoskeletal tissues, reducing inflammation, and enhancing the body’s natural repair mechanisms through substances such as bone grafts, growth factors, stem cells, and platelet-rich plasma. For example, in July 2025, the Bureau of Infrastructure and Transport Research Economics (BITRE), an Australia-based government agency, reported 1,340 road deaths, representing a 2.9% increase compared to the 12 months ending July 2024. Therefore, the increasing number of sports injuries and road accidents is expected to propel the orthobiologics market.

Companies in the orthobiologics market are focusing on developing advanced solutions, such as dry allograft mixtures, to improve bone healing and fusion in orthopedic procedures. Dry allograft mixtures combine robust cortical fibers with mineralized cortical bone to provide structural support and promote osteoinductive properties that facilitate new bone formation. For instance, in May 2024, Isto Biologics, a US-based biologics-focused company, launched Fibrant Liberty allograft, a dry allograft mixture that integrates cortical fibers with mineralized cortical cancellous chips. Upon hydration, the graft becomes pliable, customizable for various surgical procedures, and forms an intricate network that enhances handling, prevents graft migration, and maintains structural integrity.

In February 2023, Zimmer Biomet Holdings Inc., a US-based medical technology company, acquired Embody Inc. for $155 million. This acquisition allows Zimmer to invest in high-growth areas and underscores its commitment to delivering innovative solutions for patients and surgeons. The acquisition includes Embody’s portfolio of collagen-based biointegrative products designed to support healing in complex orthopedic soft tissue injuries. Embody is a US-based company specializing in the development and manufacturing of collagen-based biologic products for soft tissue augmentation and repair.

Major companies operating in the orthobiologics market are Johnson & Johnson, Medtronic plc, Zimmer Biomet, Arthrex Inc., Integra Lifesciences Corporation, NuVasive Inc., Globus Medical, Bioventus, MTF Biologics, ATEC Spine Inc., Exactech Inc., SeaSpine, RTI Surgical, AlloSource, XTANT MEDICAL, Spine Wave Inc., Bone Biologics Corp., Locate Bio Limited, Wright Medical Group N.V., BoneSupport AB, Graftys, Regenexx, Acumed LLC, Baxter International Inc., LifeNet Health.

North America was the largest region in the orthobiologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orthobiologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the orthobiologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the orthobiologics market by increasing costs for imported bone grafts, growth factors, stem cell products, and specialized laboratory equipment. These effects are most visible in cellular allograft, BMP, and synthetic bone substitute segments across north america, europe, and asia-pacific. Tariffs have led to higher treatment costs and slowed adoption in some regions. However, they have also encouraged local manufacturing of orthobiologics, strengthened regional supply chains, and driven investment in domestic production facilities.

The orthobiologics market research report is one of a series of new reports that provides orthobiologics market statistics, including orthobiologics industry global market size, regional shares, competitors with a orthobiologics market share, detailed orthobiologics market segments, market trends and opportunities, and any further data you may need to thrive in the orthobiologics industry. This orthobiologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Orthobiologics are therapies derived from natural substances used to treat musculoskeletal conditions. These therapies support the body’s ability to repair and regenerate bones, cartilage, tendons, and ligaments in orthopedic treatments, aiming to improve recovery and outcomes in procedures such as spinal fusion, fracture repair, and joint reconstruction.

The main orthobiologic products include viscosupplements, bone growth factors, demineralized bone matrix, synthetic bone substitutes, cellular allografts, and others. Viscosupplements are gel-like substances injected into joints to provide lubrication and cushioning, reducing pain and improving mobility for individuals with osteoarthritis. These products are applied in spinal fusion, maxillofacial and dental procedures, soft tissue repair, reconstructive surgery, fracture surgery, and other applications. End users include hospitals, orthopedic clinics, ambulatory surgery centers, and other healthcare facilities.

The orthobiologics market consists of sales of bone morphogenetic proteins, hyaluronic acid, stem cells, and platelet-rich plasma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.